![]() ![]() Generic Pharmaceuticals reported sales of $136 million in the quarter, down 38% due to continued competitive pressure on certain key products. The decrease was somewhat offset by increased Vasostrict revenues. Sterile Injectables revenues came in at $251.4 million, down 5% year over year as a result of lower Aplisol revenues due to a nonrecurring resupply benefit witnessed in third-quarter 2019 and the ongoing competitive pressure on certain products. However, Established Products revenues decreased 2% to $83.5 million. ![]() Sales of Xiaflex increased 7% to $88.1 million. Within the segment, Specialty Products revenues increased 6% to $140.1 million. ![]() Two Affiliate Companies Joined Endo International plc BankruptcyĮarnings Flash (ENDPQ) ENDO INTERNATIONAL Reports Q1 Adjusted EPS $0.82Įarnings Flash (ENDPQ) ENDO INTERNATIONAL Reports Q1 Revenue $515.3MĮarnings Flash (ENDPQ) ENDO INTERNATIONAL Posts Q1 Revenue $515MĮarnings Flash (ENDPQ) ENDO INTERNATIONAL Reports Q1 EPS $0.Endo International plc Price, Consensus and EPS SurpriseĮndo International plc price-consensus-eps-surprise-chart | Endo International plc Quote Quarterly HighlightsĮndo has four reportable business segments - Branded Pharmaceuticals, Generic Pharmaceuticals, Sterile Injectables and International Pharmaceuticals.īranded Pharmaceuticals revenues were $223.6 million, up 3% year over year. Premier Forms Pitocin Supply Partnership With Endo InternationalĮndo International plc Launches First Generic Version of Noxafil® (posaconazole) InjectionĮndo International plc Announces Approval of XCOPRI (Cenobam Tablets) in CanadaĮndo International plc Announces First Patient Enrolled in Registry of Dupuytren's ContractureĮndo International plc Launches Dexlansoprazole Capsules, Generic Version of DexilantĮndo International plc Launches PREVDUO (Neostigmine Mylsulfate and Glycopyrrolate Injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe Second Motion for Exclusivity Period Extension Approved For Endo International plcīankrupt Endo says US government objections imperil $600 million in opioid settlements Tranche Update on Endo International plc (OTCPK:ENDP.Q)'s Equity Buyback Plan announced on April 30, 2015.Įndo International plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023Įarnings Flash (ENDP) ENDO INTERNATIONAL Posts Q2 Revenue $547MĮarnings Flash (ENDP) ENDO INTERNATIONAL Reports Q2 EPS $0.98 Rite Aid joins companies going bankrupt amid opioid litigation Third Motion for Exclusivity Period Extension Approved For Endo International plcĮndo International plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023Įndo International plc Revises Earnings Guidance for the Year 2023Įarnings Flash (ENDPQ) ENDO INTERNATIONAL Reports Q3 EPS $0.56Įarnings Flash (ENDPQ) ENDO INTERNATIONAL Reports Q3 Revenue $451.7M Diluted loss per share was USD 11.42 compared to USD 0.22 a year ago. Basic loss per share was USD 11.42 compared to USD 0.22 a year ago. Diluted loss per share from continuing operations was USD 11.35 compared to USD 0.05 a year ago. Basic loss per share from continuing operations was USD 11.35 compared to USD 0.05 a year ago. Net loss was USD 2,679.57 million compared to USD 51.18 million a year ago. Diluted loss per share was USD 3.07 compared to USD 0.33 a year ago.įor the nine months, sales was USD 1,763.06 million compared to USD 2,203.78 million a year ago. Basic loss per share was USD 3.07 compared to USD 0.33 a year ago. Diluted loss per share from continuing operations was USD 3.05 compared to USD 0.21 a year ago. Basic loss per share from continuing operations was USD 3.05 compared to USD 0.21 a year ago. Net loss was USD 722.17 million compared to USD 77.21 million a year ago. For the third quarter, the company reported sales was USD 541.69 million compared to USD 772.03 million a year ago. Endo International plc reported earnings results for the third quarter and nine months ended September 30, 2022. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |